Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
795
datasets available to search
ShareScore release 0.9.0
Dataset results
795 results for “Drug Safety”
Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19
ClinicalTrials.gov study NCT05365321. IPD Sharing: YES. Countries: 1. Publications: 0.
Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia
ClinicalTrials.gov study NCT00203229. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Data from: Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry
Open the record for dataset details and reuse information.
Data from: Prescription of antibiotics at drug shops and strategies to improve quality of care and patient safety: a cross-sectional survey in the private sector in Uganda
Open the record for dataset details and reuse information.
Data from: Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion
Open the record for dataset details and reuse information.
Efficacy and safety evaluation of a new antidepressant drug agomelatine in the treatment of post-stroke depression: a single-center clinical study
<p><b><span>Objective: </span></b>To compare the effects of agomelatine and sertraline hydrochloride on the clinical efficacy, neurocytokine and monoamine transmitter metabolism in patients with post-stroke depression. </p> <p><b><span>Methods:</span></b> A total of 94 patients with post-stroke depression admitted to our hospital from July 2015 to September 2018 were randomly divided into a test group and a control group with 47 cases each. The experimental group was treated with agomelatine 25 mg/d orally, which was increased to 50 mg/d after 1 week, and the control group was treated with sertraline hydrochloride 50 mg/d. The two groups were treated continuously for 8 weeks. The clinical efficacy, the incidence of adverse reactions and the Hamilton Depression Scale (HAMD) before and after treatment, the National Institutes of Health Stroke Scale (NIHSS) score, BI index, and neurocytokines were compared between the two groups. Derived Neurotrophic Factor: BDNF; Nerve Growth Factor: NGF), Monoamine Transmitter Metabolism (5-Hydroxytryptamine: 5-HT; 5-Hydroxyindoleacetic acid: 5-HIAA; Norepinephrine: NE) changes.</p> <p><b><span>Results:</span></b> After treatment, the total effective rates of the experimental group and the control group were 82.97% (39 cases/47 cases) and 80.85% (38 cases and 47 cases), respectively, and the difference was not statistically significant (P>0.05). After treatment, there was no statistical difference between the test group and the control group in HAMD score, NIHSS score, and BI index (P>0.05). After treatment, there was no statistically significant difference between the test group and the control group in BDNF, NGF, 5-HT, 5-HIAA and NE (P>0.05). The incidence of adverse reactions in the experimental group and the control group were 17.02% and 19.14%, respectively, and the difference was not statistically significant (P>0.05).</p> <p><b><span>Conclusion: </span></b>Agomelatine and sertraline hydrochloride have the same clinical efficacy in the treatment of post-stroke depression, and the adverse reactions are relatively mild.</p>
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
ClinicalTrials.gov study NCT06847464. IPD Sharing: NO. Countries: 1. Publications: 0.
To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers
ClinicalTrials.gov study NCT05433844. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis
ClinicalTrials.gov study NCT06248814. IPD Sharing: NO. Countries: 5. Publications: 0.
A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis
ClinicalTrials.gov study NCT01600963. IPD Sharing: Not stated. Countries: 17. Publications: 0.
Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®
ClinicalTrials.gov study NCT03061838. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
ClinicalTrials.gov study NCT07271225. IPD Sharing: NO. Countries: 1. Publications: 0.
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
ClinicalTrials.gov study NCT05853835. IPD Sharing: NO. Countries: 2. Publications: 0.
Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System
ClinicalTrials.gov study NCT02328781. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants
ClinicalTrials.gov study NCT05107336. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
ClinicalTrials.gov study NCT02698852. IPD Sharing: NO. Countries: 1. Publications: 0.
Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Center, Non-randomized, Phase I Clinical Trial
ClinicalTrials.gov study NCT06638970. IPD Sharing: YES. Countries: 1. Publications: 0.
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
ClinicalTrials.gov study NCT07069699. IPD Sharing: YES. Countries: 1. Publications: 0.
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast
ClinicalTrials.gov study NCT07137416. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
ClinicalTrials.gov study NCT07390955. IPD Sharing: NO. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.